• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation in Patients With Obesity.

作者信息

Jackson Larry R

机构信息

Duke University Medical Center, Durham, North Carolina, USA.

出版信息

JACC Case Rep. 2024 Nov 20;29(22 Suppl):102685. doi: 10.1016/j.jaccas.2024.102685.

DOI:10.1016/j.jaccas.2024.102685
PMID:39790116
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11707371/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d6b/11707371/af08348b4a81/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d6b/11707371/af08348b4a81/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d6b/11707371/af08348b4a81/fx1.jpg

相似文献

1
Anticoagulation in Patients With Obesity.肥胖患者的抗凝治疗
JACC Case Rep. 2024 Nov 20;29(22 Suppl):102685. doi: 10.1016/j.jaccas.2024.102685.
2
Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?我们是否应该重新将既往静脉血栓栓塞事件纳入房颤抗凝决策？
Am J Med. 2021 Jan;134(1):67-75.e5. doi: 10.1016/j.amjmed.2020.05.042. Epub 2020 Jul 4.
3
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
4
Controversies and challenges of anticoagulation therapy in obesity.肥胖人群抗凝治疗的争议与挑战
Expert Opin Pharmacother. 2025 Mar;26(4):381-431. doi: 10.1080/14656566.2025.2462766. Epub 2025 Mar 17.
5
Apixaban for Treatment of Atrial Fibrillation and Venous Thromboembolism After Lung Transplantation.阿哌沙班用于肺移植术后房颤和静脉血栓栓塞的治疗。
Prog Transplant. 2023 Jun;33(2):175-181. doi: 10.1177/15269248231164173. Epub 2023 Mar 20.
6
Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion.CHA2DS2-VASc评分大于1的房颤患者在复律前口服抗凝治疗有益。
Int J Cardiol. 2016 Jul 15;215:360-3. doi: 10.1016/j.ijcard.2016.04.031. Epub 2016 Apr 11.
7
[Oral anticoagulation for prevention of thromboembolism in non-rheumatic atrial fibrillation: indications, effectiveness and risk].[口服抗凝药预防非风湿性心房颤动血栓栓塞：适应证、有效性及风险]
Z Kardiol. 1993 Nov;82(11):667-73.
8
Atrial fibrillation and anticoagulation in patients with breast cancer.心房颤动和乳腺癌患者的抗凝治疗。
Scand Cardiovasc J. 2019 Oct;53(5):247-254. doi: 10.1080/14017431.2019.1638517. Epub 2019 Jul 9.
9
Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: a single-center experience.经皮左心耳封堵术预防口服抗凝治疗禁忌或失败的心房颤动患者血栓栓塞：单中心经验
Rev Port Cardiol. 2013 Jun;32(6):461-71. doi: 10.1016/j.repc.2012.10.011. Epub 2013 Apr 30.
10
Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH.心房颤动卒中预防和肝硬化门静脉血栓形成及静脉血栓栓塞症抗凝治疗：来自 ISTH 的 SSC 指南。
J Thromb Haemost. 2024 Sep;22(9):2653-2669. doi: 10.1016/j.jtha.2024.05.023. Epub 2024 May 31.

本文引用的文献

1
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南：心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2024 Jan 2;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017. Epub 2023 Nov 30.
2
Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration.按体重和体重指数分层的抗凝治疗与静脉血栓栓塞结局：来自退伍军人健康管理局的观察。
Circ Cardiovasc Qual Outcomes. 2021 Nov;14(11):e008005. doi: 10.1161/CIRCOUTCOMES.121.008005. Epub 2021 Nov 2.
3
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.肥胖患者使用直接口服抗凝剂治疗和预防静脉血栓栓塞症：ISTH SSC 抗凝控制小组委员会的最新沟通。
J Thromb Haemost. 2021 Aug;19(8):1874-1882. doi: 10.1111/jth.15358. Epub 2021 Jul 14.
4
Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY.阿哌沙班治疗高体重或肥胖症合并静脉血栓栓塞症患者的疗效、安全性和暴露情况：来自 AMPLIFY 的研究结果。
Adv Ther. 2021 Jun;38(6):3003-3018. doi: 10.1007/s12325-021-01716-8. Epub 2021 Apr 22.
5
Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories.不同体重指数类别中房颤患者直接口服抗凝剂的治疗结局。
JACC Clin Electrophysiol. 2021 May;7(5):649-658. doi: 10.1016/j.jacep.2021.02.002. Epub 2021 Mar 31.
6
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.在体重处于极端范围的房颤患者中，阿哌沙班与华法林的疗效和安全性。
Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
7
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.肥胖患者直接口服抗凝剂的应用：国际血栓与止血学会科学与标准化委员会的指南
J Thromb Haemost. 2016 Jun;14(6):1308-13. doi: 10.1111/jth.13323. Epub 2016 Apr 27.